Advancements in Multiple Myeloma Management

This chapter explores the management strategies for multiple myeloma, particularly focusing on the relationship between minimal residual disease (MRD) and patient survival. It presents a significant analysis of over 12,000 patients, discussing the implications of MRD as a prognostic factor and its role as an accepted endpoint for regulatory approvals. The chapter also details clinical cases and expert discussions on optimizing therapy, the use of bridging treatments before CAR T-cell therapy, and the importance of comprehensive monitoring of MRD in ensuring effective patient outcomes.